Clinical evidence summary
Durable CoQ10®
Durable CoQ10®
Durable CoQ10 was formulated by Dr. Kevin Passero based on 20 years of clinical practice—combining two patented, clinically validated ingredients that work through complementary pathways to solve the absorption problem most CoQ10 supplements never address, restore the CoQ10 that statins deplete, and deliver meaningful cardiovascular and cellular energy support where your body needs it most.
Every ingredient is backed by peer-reviewed human clinical trials—selected not just for scientific validation, but for results that hold up in the real world.
Key clinical outcomes
What the research shows
7 independent peer-reviewed outcomes across absorption, blood levels, muscle delivery and statin recovery.
↑ Blood levels · 14 days
+116%
CoQ10 plasma levels after 2 weeks of daily supplementation
Petrangolini et al., 2019
Repeated dose PK study · 12 volunteers
Dose-dependent response confirmed
↓ Oxidative stress · 1 hour
>25%
Reduction in oxidative stress markers within 1 hour of a single 300mg dose
Cicero et al., BioFactors 2022
Double-blind RCT · 20 volunteers
Acute effect confirmed vs. placebo
↑ Muscle CoQ10 · 30 days
+36%
CoQ10 levels in muscle cells after 30 days — unique to phytosome delivery
Drobnic et al., J Food Sci Nutr Res 2020
Human RCT · 11 athletes
Only CoQ10 form with muscle evidence
↑ Endothelial function
+7%
Improvement in endothelial reactivity — a key early marker of cardiovascular risk
Cicero et al., BioFactors 2022
Acute single-dose effect · Double-blind RCT
Significant vs. placebo (p<0.05)
↓ Statin fatigue · 8 weeks
−30%
Reduction in statin-associated fatigue (asthenia) in older adults on statins
Fogacci et al., PMC11242215 · 2024
60 adults · Double-Blind RCT
0% dropout · University of Bologna
↑ Absorption vs. standard
+900%
Greater total absorption versus standard CoQ10
Petrangolini et al., Current Drug Delivery 2019
Single-dose PK study PK
30mg phytosome beat 100mg standard
↑ Blood levels · 14 days
+116%
CoQ10 plasma levels after 2 weeks of daily supplementation
Petrangolini et al., 2019 Repeated dose PK study · 12 volunteers
Dose-dependent response confirmed
↓ Oxidative stress · 1 hour
>25%
Reduction in oxidative stress markers within 1 hour of a single 300mg dose
Cicero et al., BioFactors 2022 Double-blind RCT · 20 volunteers
Acute effect confirmed vs. placebo
↑ Muscle CoQ10 · 30 days
+36%
CoQ10 levels in muscle cells after 30 days — unique to phytosome delivery
Marcheggiani, Tiano et al. · Antioxidants 2023
First evidence of muscle-level delivery
Only CoQ10 form with muscle evidence
↑ Endothelial function
+7%
Improvement in endothelial reactivity — a key early marker of cardiovascular risk
Cicero et al., BioFactors 2022
Acute single-dose effect ·
Double-blind RCT
Significant vs. placebo (p<0.05)
↓ Statin fatigue · 8 weeks
−30%
Reduction in statin-associated fatigue (asthenia) in older adults on statins
Fogacci et al., PMC11242215 · 2024
60 adults · Double-Blind RCT
0% dropout · University of Bologna
↑ Absorption vs. standard
+900%
Greater total absorption versus standard CoQ10
Petrangolini et al., Current Drug Delivery 2019 Single-dose PK study
30mg phytosome beat 100mg standard
⚕ The Clinical Results in Statin Users
The Only CoQ10 with a Double-Blind RCT in Statin Users
Statins block the same pathway your body uses to produce CoQ10—depleting the nutrient your heart and muscles depend on for cellular energy. Most CoQ10 supplements raise blood levels modestly at best. None of the standard forms have ever been clinically shown to deliver CoQ10 into the muscle tissue where statin depletion actually occurs.
Ubiqsome® is the only form ever tested in a double-blind, placebo-controlled RCT in statin users.
The results are the strongest in the category.
Ingredient by ingredient
The evidence behind each dose
Clinical References
Ubiqsome® · Bioavailability & Blood Levels
Petrangolini et al., Current Drug Delivery 2019
Single-dose crossover PK study + 14-day repeated dose study. 12 healthy volunteers each. HPLC-MS/MS plasma analysis. 3× AUC vs. 100mg standard CoQ10. +116% blood levels at 2 weeks. +41% at 1 capsule/day. 48-hr sustained plasma levels confirmed.
12 Volunteers · Crossover · HPLC-MS/MS
Ubiqsome® · Endothelial & Oxidative Stress
Cicero et al., BioFactors 2022
Double-blind, randomized, placebo-controlled, crossover trial. 20 healthy young non-smoking volunteers. Assessed endothelial reactivity and total antioxidant capacity (TAC) acutely and after chronic use. +7% endothelial reactivity and >25% TAC improvement from a single 300mg dose.
20 Adults · Double-Blind · Acute + Chronic
Ubiqsome® · Statin-Associated Fatigue
Fogacci et al., PMC11242215 · 2024
Double-blind, randomized, placebo-controlled. 60 adults ages 65–80 on statins. 8 weeks. University of Bologna. 0% dropout, 100% compliance. −30% fatigue, +29.8% grip strength, +36.4% sit-to-stand, +11.1% aerobic endurance.
60 Adults · 8 Weeks · 0% Dropout
Ubiqsome® · Muscle CoQ10 Delivery
Drobnic, Riera, Artuch et al., · J Food Sci Nutr Res 2020
Randomized, interventional, controlled, single-center human trial (NCT03893864). 20 healthy male runners ages 50-65. 12 intervention, 8 control. 500mg CoQ10 phytosome (100mg CoQ10) daily for 30 days. Demanding stress protocol in 35C/50% humidity climate chamber. Muscle biopsies at Day 0 and Day 30. +36% muscle CoQ10 by HPLC (confirmed by immunofluorescence). Significant reductions in MDA and IL-6/IL-10 inflammatory cytokines. First and largest human RCT confirming muscle-level CoQ10 delivery in aging athletes.
First-ever muscle delivery evidence · Human RCT · Muscle biopsy · Aging athletes (50-65 yrs)
Quercefit® · Bioavailability
Riva et al., European Journal of Drug Metabolism
Human pharmacokinetic study comparing Quercefit® to unformulated quercetin. Up to 20-fold greater plasma levels confirmed. Dose-linear absorption demonstrated. Well-tolerated with no notable side effects. Indena SpA, Milan.
20X Bioavailability · Human PK Study
Quercefit® · Gut Stability
Di Pede, Bresciani, Calani et al. · Foods 2020
In vitro human fecal fermentation model. Phytosome-formulated quercetin only 50% degraded after 24 hours vs. 93% degradation of unformulated quercetin. Formulation-level stability advantage independent of dose.
In vitro human microbiota model · Tier 2
Quercefit® · Longevity & Stress Resistance
Romeo, Barzago, Fracasso et al. · Pharmaceuticals 2026
C. elegans in vivo model + gene expression analysis. Quercefit® at optimal 100µM extended lifespan and healthspan by ~50% under heat stress vs. vehicle controls, outperforming unformulated quercetin. Protected against H2O2-induced muscle dysfunction comparably to NAC and vitamin C. Upregulated sod-3 and gst-4 (DAF-16/FOXO longevity pathway targets), suppressed hsp-16.2 and hsp-70. Note: 100µM is a culture concentration, not a human dose equivalent.
Tier 3 — In vivo C. elegans + gene expression · FOXO3/FOXO4 human pathway analog
Quercefit® · Vascular Senolytic Activity
Double-Blind RCT · Coronary Artery Disease Patients · 2025
First double-blind RCT identifying quercetin as a potent vascular "anti-inflammaging" agent in CAD patients. Decreased post-surgical atrial fibrillation, reduced systemic inflammation markers, improved endothelial sensitivity, and reduced senescence transcriptomic signature.
Double-Blind RCT · First Senolytic Human Evidence
Ready to Try Durable CoQ10?
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. +116% CoQ10 blood level increase is from the 2-capsule/day (60mg CoQ10) group at 14 days in Petrangolini et al. 2019. The >29% oxidative stress reduction and +6% endothelial function improvement are from an acute single-dose study in 20 healthy non-smoking young adults (Cicero et al. 2022). +36% muscle CoQ10 is from a human RCT with aging athletes using muscle biopsy (Drobnic et al. 2020). Statin fatigue, strength, and performance results are from adults ages 65–80 specifically (Fogacci et al. 2024). Quercefit® 20× bioavailability is vs. unformulated quercetin. C. elegans longevity findings are preclinical. CAD study (2025, double-blind RCT in coronary artery disease patients): senescent cell reduction was observed in male participants only and was not statistically significant in female participants. Vascular inflammation and endothelial findings are more broadly applicable. Individual results may vary.
Ready to Try
Durable CoQ10?
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. "Points" refers to mmHg, the standard unit of blood pressure measurement. The −37 point systolic and −9 point diastolic reductions and 93% BP normalization rate are from Belcaro et al. 2013 (119 pre/mildly hypertensive adults, 16 weeks, 300mg Enovita®, registry study with concurrent lifestyle intervention). The +154% eNOS activation and >80% endothelin-1 reduction are from in vitro endothelial cell experiments — they describe the vasodilation mechanism, not a measured human outcome. The −13 point systolic figure is from the Perrinjaquet-Moccetti 2008 twin RCT (1,000mg Benolea®, 8 weeks). The −11.5 point result is from Susalit et al. 2011 (232 stage-1 hypertensive patients, active-controlled, 8 weeks). All results are population-specific and individual results may vary.